MedDataX Logo

Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study

NCT ID: NCT00350311

Last Updated: 2008-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a feasibility study of a multi-component intervention to enhance healthy living among young people with psychotic disorders, specifically targeting smoking and weight.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We propose a feasibility study of a multi-component intervention to enhance healthy living among young people (18 to 40 years) with psychotic disorders, specifically targeting smoking and weight. Smoking is very common amongst people with psychotic disorders (around 70% of males, and over 50% of females) and this adds to the overall cardiovascular risk for this group. Obesity is also a common problem for people with psychosis, with an estimated 40-60% being obese or overweight. Obesity in this population may contribute to adverse medical and psychological consequences. For many obese people, targeted pharmacotherapy in addition to diet and increased physical activity can assist in both weight reduction and the maintenance of gains. Similarly, smoking cessation is enhanced by use of adjunctive medications such as nicotine replacement; such strategies continue to produce abstinence rates for up to 10 years.

The proposed study will assess the feasibility of a multi-component behavioural intervention focussing on smoking cessation/diet/physical activity.

The primary outcome measures from the feasibility study are smoking cessation and reduction in body mass index (BMI). Secondary outcomes will include tolerability and safety, as well as the impact the package has on other cardiovascular risk factors including serum lipids, blood sugar levels and depression in young people with psychosis. We will also establish whether smoking cessation and reduction in obesity is correlated with gains in terms of body image, quality and enjoyment of life and reduction in depression. Based on published data, behavioural interventions for smoking cessation and diet and physical activity lead smoking cessation in 20% of people at 12 months and to modest weight loss (around 5%).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychotic Disorder Obesity Behavior, Addictive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nicotine transdermal patch/lozenge

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-40 yrs
* DSM-IV diagnosis of non-organic psychotic illness
* Obesity (BMI \> 30 or 27 if co-morbidities such as diabetes, hypertension or dyslipidaemia are present
* Current smoker ( \> 15 cigarettes per day) if also smoking cannabis regularly, they will still be able to participate

Exclusion Criteria

* Medical contraindication to exercise or use of the nicotine patch
* Intellectual disability that would significantly impair ability to participate in the program
* Inability to give informed consent (acutely psychotic potential participants will be reassessed one month post screening
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Australian Government Department of Health and Ageing

OTHER_GOV

Sponsor Role collaborator

The University of New South Wales

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amanda Baker, Assoc Prof

Role: PRINCIPAL_INVESTIGATOR

Centre for Mental Health Studies, Uni of Newcastle

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Mental Health Studies, Univeristy Of Newcastle

Newcastle, New South Wales, Australia

Site Status

School of Public Health and Community Medicine, University of New South Wales

Sydney, New South Wales, Australia

Site Status

Department of Psychiatry, Monash University, The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

Mental Health Research Institute, University of Melbourne, Royal Melbourne Hospital

Melbourne, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

95/05

Identifier Type: -

Identifier Source: org_study_id